Navigation Links
DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
Date:9/8/2009

PRINCETON, N.J., Sept. 8 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that the National Institutes of Health (NIH) has awarded DOR a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 1/2 clinical trial evaluating DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP), for the prevention of acute radiation enteritis. The award will provide DOR with approximately $500,000 over a two-year period.

The grant application included the Phase 1/2 protocol BDP-ENT-01, which is designed as a multicenter, open-label, sequential, dose-escalation study in approximately 36 patients. Patients with rectal cancer who are scheduled to undergo concurrent radiation and chemotherapy prior to surgery will be enrolled in four dose groups. The objectives of the study are to evaluate the safety and maximal tolerated dose of escalating doses of DOR201, as well as the preliminary efficacy of DOR201 for prevention of signs and symptoms of acute radiation enteritis. The study is expected to be initiated in 2009.

Acute radiation enteritis is caused by radiation-induced death of cells in the lining of the bowel. As bowel cells die and are not replaced, gastrointestinal toxicity develops over the next few days and weeks due to an inflammatory response to dead cells and bacteria, with chronic diarrhea, vomiting and pain being the major symptoms. The addition of chemotherapy often exacerbates the onset, severity and debilitation related to intestinal symptoms. Radiation enteritis often results in delay or interruption of the cancer treatment. There are over 100,000 patients annually in the United States who receive abdominal or pelvic external beam radiation treatment for cancer, and these patients are at risk of developing acute and chronic radiation enteritis.

"Radi
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
2. Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
3. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
4. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
5. CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
6. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
7. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
10. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
11. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... NEW YORK , Sept. 3, 2015 ... successfully used to save millions of lives across globe. ... the Kingdom of Saudi Arabia . ... raw material suppliers, government agencies and regulatory bodies. The ... been studied from two perspectives: by products and by ...
(Date:9/3/2015)... Sept. 3, 2015  WellCare Health Plans, Inc. (NYSE: ... , senior vice president and chief financial officer, is ... Healthcare Conference on Wednesday, September 9, 2015, at 9:25 ... webcast live. In addition, a replay of the webcast ... broadcast. Both the live broadcast and the replay will ...
(Date:9/3/2015)... RICHMOND, Va. , Sept. 3, 2015  As ... for patients with heart disease, Marc R. Katz ... of the Bon Secours Heart & Vascular Institute implanted ... August 18, 2015. The patient was selected as part ... is one of 60 elite centers in the United ...
Breaking Medicine Technology:Saudi Arabia Defibrillators Market: & Advanced Life Support Defibrillators; End Users; Industry Analysis, Size, Volume, Growth, Trends and Forecast 2014 - 2020 2Bon Secours' Patient FIRST in Central Virginia to receive New Life-saving Care 2Bon Secours' Patient FIRST in Central Virginia to receive New Life-saving Care 3Bon Secours' Patient FIRST in Central Virginia to receive New Life-saving Care 4
... BERGISCH GLADBACH, Germany, May 20 Miltenyi ... Myelin Removal Beads. Myelin,is a specialized membrane ... and central nervous system. During preparation of ... contaminant. "When,dissociating adult neural tissue, usually less ...
... New data demonstrate that maintenance therapy with RISPERDAL(R) CONSTA(R) ... relapse compared to placebo in patients with Bipolar I ... at a major medical meeting. Bipolar Disorder is ... person,s mood, energy and ability to function. It is ...
Cached Medicine Technology:Myelin Removal Beads: Premium Efficiency for Neural Cell Separations and Antibody Stainings 2RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 2RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 3RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 4RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 5RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 6RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 7RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 8RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 9RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 10
(Date:9/3/2015)... ... 03, 2015 , ... BedJet released a new version of its award winning ... Today the BedJet v2 pre-order campaign blazed past the $1 million dollar ... ever on crowdfunding giant Kickstarter. , Simple to use and beautifully designed, the award ...
(Date:9/3/2015)... ... September 03, 2015 , ... Real Time Pain Relief (RTPR), ... bull rider David Mason has signed an official endorsement deal with the company. Originally ... six and his first bull at 15. He is an Australian bull riding champion, ...
(Date:9/3/2015)... ... 2015 , ... Hope For The Warriors® is pleased to ... awarded two times each year to spouses or caregivers of post-9/11 wounded or ... restoring a sense of self, restoring the family unit, and restoring hope for ...
(Date:9/3/2015)... GA (PRWEB) , ... September 03, 2015 , ... ... cover the cost of graduated compression garments. However, graduated compression garments are an ... Wound care and lymphedema specialist, Robyn Bjork, was recently sponsored by SIGVARIS ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... landscape by connecting accredited and institutional investors to real estate investment opportunities nationwide, ... to meet demand from both investors and sponsoring real estate companies. ...
Breaking Medicine News(10 mins):Health News:BedJet Hits $1 million in Sales in 28 Days on Kickstarter after Shark Tank Rejection 2Health News:BedJet Hits $1 million in Sales in 28 Days on Kickstarter after Shark Tank Rejection 3Health News:Real Time Pain Relief Sponsors the Talented PBR Bull Rider from Down Under - David Mason 2Health News:Real Time Pain Relief Sponsors the Talented PBR Bull Rider from Down Under - David Mason 3Health News:Hope For The Warriors Spouse/Caregiver Scholarships Now Open for Spring 2016 2Health News:SIGVARIS Supports the Lymphedema Treatment Act to Help Patients with Lymphedema 2Health News:SIGVARIS Supports the Lymphedema Treatment Act to Help Patients with Lymphedema 3Health News:RealtyShares Announces Mezzanine Financing Products 2Health News:RealtyShares Announces Mezzanine Financing Products 3
... taken necessary steps and planned a schedule to support employed ... that women took leave from work very often to take ... schedule of work and increased their stress level. ... wide rage of medical problems. The news paper said that ...
... medical marijuana, concerns have been raised by justices regarding allowing ... symptoms and perhaps even prolong life. A federal appeals court ... legal wrangling over the issue, this week. ,The ... the drug should be allowed, it is the only viable ...
... Statistics show that about one in 100 11-year-olds had taken ... and one in 10 of 15-year-olds// have taken hard drugs. ... pupils. They take illegal drugs such as cocaine which has ... , The survey was carried out among England's 3.4 million ...
... getting sensitive to noise, and do not like it much! ... noisy surroundings// may face an increased risk of suffering a ... chances of urban middle-aged adults, living on high-traffic ... percent chance of suffering heart attack, than those who lived ...
... Even though mental disorders are said to account for ... studies have been undertaken to assess// this assumption in ... as part of the WHO World Mental Health (WMH) ... 2857 adults was done in Lebanon between September, 2002, ...
... The new low nicotine Quest? cigarettes seems to have ... to a study conducted by researchers// at the Transdisciplinary ... School of Medicine.Results of the study have been published ... ,The author of this study, Caryn Lerman, PhD, Associate ...
Cached Medicine News:Health News:Cancer Patient to Appeal to SC, Demanding Right to Use Marijuana 2Health News:A National Survey Revealed That Mental Disorders Are Common In Lebanon 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: